GlassScriptPhysician profile
Geona Guappone
NPI 1932857075
$2,085.89
in general payments reported to CMS, 2019-2025
24 companies · $644 in 2025
The $644 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.16 · 2023: $710 · 2024: $676 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,029.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $669.93 | 2023-2025 | Breztri, Farxiga, Lokelma |
| Pfizer INC. | $343.91 | 2023-2025 | |
| Lilly USA, LLC | $240.02 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $203.51 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.61 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $62.07 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbvie INC. | $61.63 | 2022-2024 | |
| Axsome Therapeutics, INC. | $57.61 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $45.23 | 2025 | |
| Exact Sciences Corporation | $38.08 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $34.84 | 2024 | Trintellix |
| Radius Health, INC. | $34.31 | 2025 | Tymlos |
| Viatris Specialty LLC | $23.42 | 2025 | Yupelri |
| Pulmonx Corporation | $22.68 | 2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.26 | 2025 | Caplyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.70 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.46 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.41 | 2025 | Rexulti |
| Lundbeck LLC | $15.25 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $15.18 | 2025 | Voquezna |
| Athena Bioscience, LLC | $14.96 | 2023 | Qdolo |
| Grifols USA, LLC | $14.71 | 2024 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $14.10 | 2023 | Shingrix |
| Shield Therapeutics INC | $13.01 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geona Guappone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.